Press releases

MARLBOROUGH, Mass., Oct. 11, 2023 -- Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha™...

Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass., Sept. 19, 2023 /PRNewswire/ -- Boston...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific...

Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine...

First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational1 basis...

MARLBOROUGH, Mass., Jul. 11, 2023 -- Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the Vercise™ Neural Navigator 5 Software,...

Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis...

New technology designed to help inform real-time clinical decisions during kidney stone procedures MARLBOROUGH, Mass., Feb. 3, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today...